Monday 1 July 2024

The Pharma Letter Podcast — Episode 24 — Lilly looks to lead in Alzheimer's

Biotechnology
Simon Wentworth
17 July 2023
pharma_letter_podcast_24

More on this story...

Biotechnology
New Alzheimer's therapies ready for battle at AAIC 2023
12 July 2023
Biotechnology
New Alzheimer's antibodies: AAIC rings bell for first round face off
18 July 2023
Biotechnology
The week in pharma: action, reaction and insight – week to July 21, 2023
23 July 2023
Biotechnology
Coya Therapeutics expands COYA 302 into Alzheimer’s disease
21 February 2024


Related Company News

Eisai’s strategic collaboration with Bristol Myers Squibb ended
Alzheimer’s drug Leqembi launched in China
EU taking action to tackle GLP-1 receptor agonist shortages
BRIEF—TGA update on GLP-1 RAs pharmacy compounding changes
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze